Company facts
- Headquarters
- Saint-Laurent
- Most recent report
- 10-Q, filed Sep 8, 2026
- Filings on record
- 266 filings
- On EDGAR
- CIK 1980845
- Fiscal year ends
- October
- Filer status
- Emerging growth company
Financials 8 of 14
News 8 of 46
Prospectuses and Registrations 8 of 30
- S-8 Registration statement for an employee plan Mar 9, 2026
- 424B5 Prospectus supplement for an offering Mar 9, 2026
- S-3 Shelf registration statement Feb 19, 2026
- 424B5 Prospectus supplement for an offering Nov 14, 2025
- 424B5 Prospectus supplement for an offering Nov 12, 2025
- S-8 Registration statement for an employee plan Sep 11, 2025
- S-8 Registration statement for an employee plan Mar 10, 2025
- 424B5 Prospectus supplement for an offering Dec 20, 2024
Proxies 3
Ownership 8 of 139
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 12, 2026
- 3 Insider reported their initial holding Jul 22, 2026
- 3 Insider reported their initial holding Jul 22, 2026
- SCHEDULE 13G Large holder reported a passive stake Jul 22, 2026
Other 8 of 34
- ARS Annual report sent to shareholders May 8, 2026
- EFFECT Notice that a registration became effective Mar 2, 2026
- CORRESP Reply to SEC staff Feb 26, 2026
- UPLOAD Comment letter from SEC staff Feb 25, 2026
- ARS Annual report sent to shareholders May 9, 2025
- EFFECT Notice that a registration became effective Nov 21, 2024
- EFFECT Notice that a registration became effective Nov 21, 2024
- CORRESP Reply to SEC staff Nov 19, 2024
Everything here comes from enGene Therapeutics Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.